» Articles » PMID: 36452503

The Global Research of Bladder Cancer Immunotherapy from 2012 to 2021: A Bibliometric Analysis

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Dec 1
PMID 36452503
Authors
Affiliations
Soon will be listed here.
Abstract

Intravesical instillation of Bacillus Calmette-Guérin has been used as an immunotherapy to treat superficial bladder cancer for almost half a century. In recent years, the approval of several monoclonal antibody treatments has transformed the treatment landscape for patients with muscle-invasive or metastatic uroepithelial carcinoma. The purpose of this study was to conduct a thorough review of immunotherapy in bladder cancer through a bibliometric approach. Publications related to bladder cancer immunotherapy were obtained from the Web of Science Core Collection on July 1st, 2022. We conducted a bibliometric analysis of literature information using CiteSpace IV, VOSviewer, and Scimago Graphica, including co-authorship or co-citation of authors, countries/regions, journals, references, and keyword co-occurrence. There was a total of 2,352 papers included, with the most contributions coming from the United States, China, and Italy. The United States had the highest H-index value and was the leading country in this field. Meanwhile, the number of publications in China was steadily growing. The top three productive researchers were Kamat AM, Necchi A, and Shariat SF, with Powles T as the top co-cited author. Most papers were published by the University of Texas System. The majority of papers in this field were published in and was the most influential journal with the highest H-index. The tumor microenvironment and complete molecular characterization may still be the frontier in this research area, allowing us to obtain a better understanding of the pathogenesis and clinical prognosis of bladder cancer. More research are conducted to identify clinically meaningful biomarkers that may provide opportunities for the personalization of bladder cancer therapy. This study provides clinicians and researchers with an overview and helpful guidance on how to choose the research direction and management of bladder cancer immunotherapy.

Citing Articles

A scientometric review of the growing trends in transcranial alternating current stimulation (tACS).

Liu Y, Luo Y, Zhang N, Zhang X, Liu S Front Hum Neurosci. 2024; 18:1362593.

PMID: 38510513 PMC: 10950919. DOI: 10.3389/fnhum.2024.1362593.


A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues.

Huang Y, Liao C, Shen Z, Zou Y, Xie W, Gan Q Front Immunol. 2024; 15:1297542.

PMID: 38444854 PMC: 10912866. DOI: 10.3389/fimmu.2024.1297542.


Emergent trends in organ-on-a-chip applications for investigating metastasis within tumor microenvironment: A comprehensive bibliometric analysis.

He C, Lu F, Liu Y, Lei Y, Wang X, Tang N Heliyon. 2024; 10(1):e23504.

PMID: 38187238 PMC: 10770560. DOI: 10.1016/j.heliyon.2023.e23504.


Astragalus polysaccharide inhibits the development of urothelial carcinoma by activating AMPK signaling to induce BENC1-xCT complex formation.

Tong G, Wang X, Chen S, Jin Y Aging (Albany NY). 2023; 15(18):9438-9452.

PMID: 37733667 PMC: 10564440. DOI: 10.18632/aging.205007.


Inflammation-related research within the field of bladder cancer: a bibliometric analysis.

Deng Z, Tang N, Xiong W, Lei X, Zhang T, Yang N Front Oncol. 2023; 13:1126897.

PMID: 37350946 PMC: 10282760. DOI: 10.3389/fonc.2023.1126897.

References
1.
Kamat A, Hahn N, Efstathiou J, Lerner S, Malmstrom P, Choi W . Bladder cancer. Lancet. 2016; 388(10061):2796-2810. DOI: 10.1016/S0140-6736(16)30512-8. View

2.
Huang M, Liu L, Zhu J, Jin T, Chen Y, Xu L . Identification of Immune-Related Subtypes and Characterization of Tumor Microenvironment Infiltration in Bladder Cancer. Front Cell Dev Biol. 2021; 9:723817. PMC: 8438153. DOI: 10.3389/fcell.2021.723817. View

3.
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J . Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017; 18(3):312-322. DOI: 10.1016/S1470-2045(17)30065-7. View

4.
Lobo N, Brooks N, Zlotta A, Cirillo J, Boorjian S, Black P . 100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. Nat Rev Urol. 2021; 18(10):611-622. PMC: 8204595. DOI: 10.1038/s41585-021-00481-1. View

5.
Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M . Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers (Basel). 2021; 13(1). PMC: 7795541. DOI: 10.3390/cancers13010131. View